Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf in COVID-19 ARDS
NCT04384731Phase 2Unknown
- Start
- May 2020
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Poractant alfa in acute respiratory distress syndrome (ARDS) (2 arms). Primary endpoint: Evolution of the PaO2 / FiO2 ratio at 1 hour. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04384731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04384731.